Exclusive Financial Advisor to Angion Biomedica Corp.
Oppenheimer & Co. Inc. Acted as Exclusive Financial Advisor to Angion Biomedica Corp. on its Merger with Elicio Therapeutics, Inc.
On June 1, 2023, Angion Biomedica Corp. (Nasdaq: ANGN) completed its merger with Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. The combined company will operate under the name Elicio Therapeutics, and its shares commenced trading on a 1-10 reverse split-adjusted basis on June 2, 2023, on the Nasdaq Global Market under the ticker symbol “ELTX”.
The combined company will focus on advancing its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology. ELI-002 is being evaluated in the AMPLIFY-201 Phase 1 trial and a Phase 1/2 study AMPLIFY-7P in patients with mutant KRAS-driven solid tumors.
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 5722746.1